Attacks on antidepressants: signs of deep-seated stigma?

Psychiatry is used to being attacked by external parties with antidiagnosis and antitreatment agendas. However, the recent disclosure that a doctor (Professor Peter Gotzsche) had joined a new group, the Council for Evidence-based Psychiatry, whose launch was accompanied by newspaper headlines such as “Antidepressants do more harm than good, research says” and “Psychiatric drugs are doing us more harm than good” in The Times and The Guardian plumbs a new nadir in irrational polemic. What is especially worrying is that this doctor is a co-founder of the Nordic Cochrane collaboration, an initiative set up to provide the best evidence for clinical practitioners. What is the truth about antidepressant efficacy and adverse effects, and why would Professor Gotzsche apparently suspend his training in evidence analysis for popular polemic?

Depression is a serious and recurrent disorder that is currently the largest cause of disability in Europe and is projected to be the leading cause of morbidity in high-income countries by 2030. Antidepressants have an impressive effect size in the treatment of acute cases of depression, with a number needed to treat of around six. For example, the recently updated Cochrane review of amitriptyline, which involved 18 randomised controlled trials and 1987 participants, shows that it is significantly more effective than placebo in achieving acute response (odds ratio 2.67, 95% CI 2.21–3.23), and that significantly fewer participants allocated to amitriptyline than to placebo withdrew from trials because of treatment inefficacy. How can this finding represent more harm than good? A smaller proportion of treated patients withdrew because of side-effects and the pattern of results was the same in industry-sponsored and independently funded trials. Indeed, in general, effect sizes for psychiatric indications do not differ from those of drugs used in physical medicine. Moreover, antidepressants have an impressive ability to prevent recurrence of depression, with a number needed to treat of around three, which makes them one of the most effective of all drugs.

Suicide kills about 6000 people every year in the UK. Most of these people are depressed and more than 70% are not taking an antidepressant at the time of death. Blanket condemnation of antidepressants by lobby groups and colleagues risks increasing that proportion. In countries where antidepressants are used properly, suicide rates have fallen substantially.

Of course, all active drugs have adverse effects, but for the new antidepressants these are rarely severe or life-threatening, even in overdose situations. Indeed, the new antidepressants, especially the selective serotonin reuptake inhibitors, are some of the safest drugs ever made. In our experience, the vast majority of patients who choose to stay on them do so because they improve their mood and wellbeing rather than because they cannot cope with withdrawal symptoms when they stop. Many of the extreme examples of adverse effects given by the opponents of antidepressants are both rare and sometimes sufficiently bizarre as to warrant the description of an unexplained medical symptom. To attribute extremely unusual or severe experiences to drugs that appear largely innocuous in double-blind clinical trials is to prefer anecdote to evidence. The incentive of litigation might also distort the presentation of some of the claims.

Antipsychiatry groups usually claim that depressed patients should be treated with exercise and psychotherapy instead of drugs. However, little controlled evidence exists to support the use of psychotherapy as an alternative to antidepressants in major depression. Indeed, if psychotherapy had to be tested according to the same rules as drugs, then whether or not it could be licensed for this indication is questionable. Moreover, the implication that, unlike antidepressants, psychotherapy is free of adverse effects is highly misleading. Suicidal ideation and even completed suicide are recognised adverse effects with psychotherapy, and sexual interference with patients by therapists is a matter of concern. Finally, exercise treatment, as the recent Cochrane review concludes, “is moderately more effective than a control intervention for reducing symptoms of depression, but analysis of methodologically robust trials only shows a smaller effect” and exercise is no more acceptable to patients than are psychological or pharmacological treatments.

What motivates doctors with a commitment to evidence-based practice to make such a series of flawed statements about antidepressants? We can only speculate. First, general practitioners (GPs) clearly see a lot of patients with minor somatic and
psychiatric problems. We know from our contacts with GP colleagues that such patients might not be who a GP with a conventional internal medicine background years to treat. It might be comforting to believe that treatment doesn’t really matter. Second, contemporary bien pensant society remains resolutely dualist in its language and its understanding, and doctors are part of that society. The idea of a medicine for something lacking in substance (the mind) might seem a priori implausible, irrational, and undesirable. Third, the anti-psychiatry movement, although now long in the tooth, has revived itself with the recent conspiracy theory that the pharmaceutical industry, in league with psychiatrists, actively plots to create diseases and manufacture drugs no better than placebo. The anti-capitalist flavour of this belief resonates with anti-psychiatry’s strong association with extreme or alternative political views.

Whatever the reasons, extreme assertions such as those made by Prof Gøtzsche are insulting to the discipline of psychiatry and at some level express and reinforce stigma against mental illnesses and the people who have them. The medical profession must challenge these poorly thought-out negative claims by one of its own very vigorously.

*David J Nutt, Guy M Goodwin, Dinesh Bhugra, Seena Fazel, Stephen Lawrie
Imperial College London, London, UK (DJN); University of Oxford, Oxford, UK (GMG, SF); Kings College London, London, UK (DB); and University of Edinburgh, Edinburgh, UK (SL)
d.nutt@imperial.ac.uk

DJN has received grants and personal fees from Lundbeck and GSK; and personal fees from Lilly, BMS, Otsuka, Servier, and Pfizer. GMG has received grants and personal fees from Servier and Lundbeck; personal fees from Teva, Otsuka, Takeda, Eli Lilly, Merck, GSK, and AstraZeneca; and grants from P1vital. DJN and GMG have a small number of stocks in P1vital. A CNS experimental medicine research consultancy company. SL has received research funding from Abbvie, Roche, and Pfizer in connection with genetic, brain imaging, and therapeutic studies of people with schizophrenia. He has also been paid by Janssen and Roche to speak at or chair educational meetings about schizophrenia, as well as to contribute to advisory boards about new anticlofacic treatments. The other authors declare no competing interests.